Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 255

Posts Tagged ‘scientific sessions’

The Medicines Company Presents New Data at the National Lipid Association Scientific Sessions

Posted by fidest press agency su giovedì, 3 maggio 2018

The Medicines Company (NASDAQ:MDCO) presented important new data and analyses from the ORION development program for inclisiran at the National Lipid Association (NLA) 2018 Scientific Sessions held in Las Vegas, NV. Multiple studies in the ORION development program demonstrate that the proposed dosing regimen is likely to be the same for a wide range of dyslipidemia patient populations, including those hard-to-treat patients with homozygous familial hypercholesterolemia (HoFH) and other sub-groups.Dr. David Kallend, MBBS, Chief Medical Officer of The Medicines Company, presented a range of new data and analysis during a Late Breaker session titled “The Efficacy and Safety of Inclisiran, An RNAi Therapeutic Targeting PCSK9, in Different Patient Populations”, demonstrating that the inclisiran dosing regimen (300 mg injection administered on Day-1, Day-90 and then every six months thereafter) achieved substantial PCSK9 and low-density lipoproteins cholesterol (LDL-C) lowering in patients with HoFH and primary dyslipidemia, as well as in various sub-groups, such as patients with renal impairment and diabetes. The data showed that inclisiran lowered LDL-C by more than 50% across a wide range of dyslipidemia patient populations and sub-groups, and by up to 44% in HoFH patients.Commenting on the data, Principal Investigator for the ORION-1 and ORION-11 trials, Professor Kausik Ray, Professor of Public Health, Imperial College London, United Kingdom, and honorary consultant cardiologist, Imperial College NHS Trust, said, “The data demonstrate, yet again, inclisiran’s emerging, best-in-class therapeutic profile, as well as its potential to address the unmet needs of millions of at-risk, often non-adherent, patients worldwide who continue to struggle with high cholesterol given the limitations of available therapies.”
John J.P. Kastelein, M.D., Ph.D., Professor of Medicine and Chairman of the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, and Chairman of the ORION-1 and ORION-9, ORION-10 and ORION-11 Steering Committees, said, “New therapies are needed to treat HoFH who are refractory or intolerant to current approaches for the management of their LDL-C levels. The simplicity and convenience of a one-size-fits-all dosing regimen, without the necessity of dose adjustment, is a highly-attractive therapeutic option for health care professionals, and could make a significant difference in busy clinical practice.”Dr. Kallend added, “The data presented confirm the consistent efficacy of inclisiran’s dosing regimen across all patient populations and sub-groups, with no safety concerns observed in any patient population.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »